Latest Expert Opinions

Signal
Opinion
Expert
STRONG BUY
STRONG BUY
March 14, 2018

A great performer in competition with Amazon. It won't rollover against Amazon, but compete. FedEx's e-commerce business is propelling its growth. Also, we're on the verge of the driverless car, which will greatly save costs for FedEx. Good earnings. Well-managed. Expanding internationally, though a cyber attack last year cost them, Overall, great opportunity here.

Show full opinionHide full opinion
FedEx (FDX-N)
March 14, 2018

A great performer in competition with Amazon. It won't rollover against Amazon, but compete. FedEx's e-commerce business is propelling its growth. Also, we're on the verge of the driverless car, which will greatly save costs for FedEx. Good earnings. Well-managed. Expanding internationally, though a cyber attack last year cost them, Overall, great opportunity here.

BUY
BUY
March 14, 2018

This will reward patient investors. A highly-disrupted business, having just bought insurer Aetna for vertical integration. They are redefining themselves by locating a store within 3 miles of 80% of the US population, a population that now must take care of chronic ailments, like diabetes. So, this proximity to customers is efficient and profitable. Trading at 11x earnings with good cash flow despite current debt levels. Also likes competitor Walgreens.

Show full opinionHide full opinion
CVS Health Corp (CVS-N)
March 14, 2018

This will reward patient investors. A highly-disrupted business, having just bought insurer Aetna for vertical integration. They are redefining themselves by locating a store within 3 miles of 80% of the US population, a population that now must take care of chronic ailments, like diabetes. So, this proximity to customers is efficient and profitable. Trading at 11x earnings with good cash flow despite current debt levels. Also likes competitor Walgreens.

BUY
BUY
March 14, 2018

Long held this, and it's a good peformer. Processed 1.9 trillion transactions last year. Growing at a 20% annual rate. Multiple around low-mid-20s. High in earnings predictability with no surprises. 61% of business is outside North America. All good.

Show full opinionHide full opinion
Visa Inc. (V-N)
March 14, 2018

Long held this, and it's a good peformer. Processed 1.9 trillion transactions last year. Growing at a 20% annual rate. Multiple around low-mid-20s. High in earnings predictability with no surprises. 61% of business is outside North America. All good.

BUY
BUY
March 14, 2018

All the home builders have struggled in reaction to higher interest rates. But these rates are starting from a very low place and won't go very high. 2008 remains fresh in the minds of the Fed, so they are sensitive to the impact of rising rates. New home creation is still below trend in the U.S., so there's a lot of runway here.

Show full opinionHide full opinion

All the home builders have struggled in reaction to higher interest rates. But these rates are starting from a very low place and won't go very high. 2008 remains fresh in the minds of the Fed, so they are sensitive to the impact of rising rates. New home creation is still below trend in the U.S., so there's a lot of runway here.

STRONG BUY
STRONG BUY
March 14, 2018

He once sold it, because he saw Disney trapped in cord cutting so their cable subscribers were dropping. But after the 20th Century Fox purchase, he changed his mind. Disney's new streaming service through Hulu will compete with Netflix. An exciting opportunity here.

Show full opinionHide full opinion
Walt Disney (DIS-N)
March 14, 2018

He once sold it, because he saw Disney trapped in cord cutting so their cable subscribers were dropping. But after the 20th Century Fox purchase, he changed his mind. Disney's new streaming service through Hulu will compete with Netflix. An exciting opportunity here.

PAST TOP PICK
PAST TOP PICK
March 14, 2018

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

Show full opinionHide full opinion

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

PAST TOP PICK
PAST TOP PICK
March 14, 2018

(A Top Pick March 16/17, Up 11%) Enjoyed 7.4% loan growth in 2017. A steady eddy with room to grow driven by margin expansion (high interest rates) and loan growth due to robust U.S. economy.

Show full opinionHide full opinion

(A Top Pick March 16/17, Up 11%) Enjoyed 7.4% loan growth in 2017. A steady eddy with room to grow driven by margin expansion (high interest rates) and loan growth due to robust U.S. economy.